Trials / Available
AvailableNCT03462810
GSK1265744 (Cabotegravir, CAB) for Named Patient/Compassionate Use in HIV
- Status
- Available
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- ViiV Healthcare · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- —
Summary
The goal of this compassionate use program is to provide a mechanism to supply Cabotegravir, CAB on an individual named patient basis for treatment of individuals who have no available treatment alternatives and/or limited treatment options (e.g., who are unable to participate in the Phase III clinical studies or do not qualify), and are in need of new drugs to construct an effective antiviral regimen and may require the use of parenterally administered drug given underlying medical conditions. You can access ViiV's Policy on Compassionate via https://us.viivhealthcare.com/media/124424/viivs-external-policy-on-cup\_final-version\_23feb2017.pdf.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | cabotegravir, CAB | open label investigational product |
Timeline
- First posted
- 2018-03-13
- Last updated
- 2021-05-21
Source: ClinicalTrials.gov record NCT03462810. Inclusion in this directory is not an endorsement.